{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:07:13Z","timestamp":1779188833537,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This post hoc analysis of the CHAMPION-NMOSD trial evaluated the safety and efficacy of ravulizumab in patients with aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) previously exposed or na\u00efve to rituximab (RTX).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients received weight-based intravenous ravulizumab with a loading dose followed by maintenance dosing every 8\u2009weeks. Patients were stratified by prior RTX exposure: no RTX exposure (RTX-na\u00efve) vs RTX exposure\u2009&gt;\u20093\u2009months before initiating ravulizumab (RTX-exposed). Key outcomes included treatment-emergent adverse events (TEAEs), serious TEAEs (TESAEs), relapse rates, and vaccination timing from the last RTX dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 58 patients enrolled, 89.7% were female, with a mean age of 47.4\u2009years, and 21\/58 (36.2%) were RTX-exposed. Relapses occurred in 12\/21 (57.1%) RTX-exposed patients between their first RTX dose and study entry. The safety profile of ravulizumab was generally similar between RTX-exposed and RTX-na\u00efve groups. Common TEAEs included COVID-19, headache, urinary tract infection, and upper respiratory tract infection. UTIs were more frequent in RTX-exposed individuals. One patient in each group experienced a meningococcal infection. No adjudicated on-trial relapses were reported while on ravulizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Following initiation of ravulizumab, RTX-exposed and RTX-na\u00efve patients with AQP4-Ab+\u2009NMOSD achieved sustained disease control and demonstrated a manageable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Information:<\/jats:title>\n                    <jats:p>The CHAMPION-NMOSD Trial; ClinicalTrials.gov identifier: NCT04201262 (registered October 06, 2020).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585261425076","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:43:15Z","timestamp":1773225795000},"page":"396-408","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial"],"prefix":"10.1177","volume":"32","author":[{"given":"JL","family":"Bennett","sequence":"first","affiliation":[{"name":"Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mass General Brigham, Boston, MA, USA; Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Zabeti","sequence":"additional","affiliation":[{"name":"University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"M","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mass General Brigham, Boston, MA, USA; Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7197-7578","authenticated-orcid":false,"given":"J","family":"de S\u00e8ze","sequence":"additional","affiliation":[{"name":"H\u00f4pital Civil, Service de Neurologie, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"Taney","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Parks","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Allen","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-5869","authenticated-orcid":false,"given":"U","family":"Akpoji","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-6491","authenticated-orcid":false,"given":"SJ","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02249-1"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2018170141"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30066-1"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084154"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.1276"},{"key":"e_1_3_3_8_2","unstructured":"RITUXAN\u00ae (rituximab) [Prescribing Information]. Genentech Inc. https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf (2021 accessed 16 December 2025)."},{"key":"e_1_3_3_9_2","unstructured":"UPLIZNA\u00ae (inebilizumab-cdon) [Prescribing Information]. Amgen Inc. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/uplizna\/uplizna_fpi_english.pdf (2025 accessed 16 December 2025)."},{"key":"e_1_3_3_10_2","unstructured":"Hanif N Anwer F. Rituximab https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564374\/"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00487-6"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552173241257876"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac608"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104400"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2025.100271"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26049"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00077-2"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103352"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102641"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","unstructured":"Bennett JL Akpoji U Bhattacharyya S et al. Time to vaccination after rituximab (RTX) discontinuation in patients with anti\u2013aquaporin-4 antibody\u2013positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): A post hoc analysis of the CHAMPION-NMOSD trial. In: Americas committee for treatment and research in multiple sclerosis West Palm Beach FL 27 February\u20131 March 2025.","DOI":"10.1212\/WNL.0000000000208553"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104321"},{"key":"e_1_3_3_27_2","unstructured":"Ultomiris approved in Japan for the prevention of relapses in patients with NMOSD https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-nmosd.html (2023 accessed 28 March 2025)."},{"key":"e_1_3_3_28_2","unstructured":"Ultomiris approved in the EU and for adults with neuromyelitis optica spectrum disorder (NMOSD) https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html (2023 accessed 28 March 2025)."},{"key":"e_1_3_3_29_2","unstructured":"ULTOMIRIS\u00ae (ravulizumab-cwvz) [Prescribing Information]. Alexion Pharmaceuticals Inc. https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2025\/english\/ultomiris_uspi.pdf?rev=7ab9a5262ccb4e56a42a560d3107082d (accessed 16 December 2025)."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00568-8"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1352779"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241269219"},{"issue":"7","key":"e_1_3_3_33_2","first-page":"211203","article-title":"AAN 2025\u2014Relapse, non-relapse and treatment outcomes in a real-world neuromyelitis optica spectrum disorder cohort","volume":"107","author":"Bilodeau PA","year":"2025","unstructured":"Bilodeau PA, Wruble M, Narasimhan S, et al. AAN 2025\u2014Relapse, non-relapse and treatment outcomes in a real-world neuromyelitis optica spectrum disorder cohort. Neurology 2025;107(7): 211203.","journal-title":"Neurology"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01191-7"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201260"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1884223"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103505"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010380"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1086\/515075"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501254102"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2494"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2025-004651"},{"key":"e_1_3_3_45_2","unstructured":"Ultomiris (ravulizumab) Summary of Product Characteristics\u2014Product Information (SmPC) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf (August 2025)."},{"key":"e_1_3_3_46_2","unstructured":"Akpoji U Pandya S Aguzzi R et al. Characterization of antibiotic prophylaxis risk mitigation practices across eculizumab and ravulizumab phase 3 clinical trials in adults with PNH aHUS gMG and NMOSD. In: Scientific Session of the Myasthenia Gravis Foundation of America Inc. (MGFA) San Francisco CA 2025 https:\/\/online.flippingbook.com\/view\/442003187\/349\/"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261425076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261425076","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261425076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:14:07Z","timestamp":1779185647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261425076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/13524585261425076"],"URL":"https:\/\/doi.org\/10.1177\/13524585261425076","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}